Board Member
Assertio Holdings, Inc.
Equibles does not estimate personal net worth.
Brendan O’Grady is recorded as Board Member at Assertio Holdings, Inc. since January 1, 2024. The newest filing on record that lists Brendan O’Grady as Board Member at Assertio Holdings, Inc. is dated April 8, 2025. Earlier roles on record: Board Member at American Well Corp (AMWL) until July 19, 2021. The proxy statement of Assertio Holdings, Inc. reports total compensation of $1,884,984 for Brendan O’Grady in fiscal 2025, including a base salary of $721,933. Disclosed compensation is on record for 5 fiscal years. Brendan O’Grady has spoken on 5 earnings calls across 1 company, most recently for Assertio Holdings, Inc. on August 11, 2025. Assertio Holdings, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“I'll begin today with a brief overview of our second quarter financial results, which showcase both execution against the transformation phase priorities I have laid out as part of our long-term business strategy and our ability to focus the business in ways that improve operating performance for our investors.”
“I'll begin today with a quick overview of our first quarter financial results, which are in line with the full-year 2025 net product sales and adjusted EBITDA expectations that were set forth during the March earnings call.”
“I'd like to start by welcoming everyone to today's call and thanking you for joining us. I'll begin my comments with some overall perspectives on 2024 and then turn the call over to AJ to discuss Q4 and 2024 full-year financials.”
“I'd like to start by wishing you all a Happy Veterans Day, especially to our retired and active service members and their families. In addition to our usual quarterly performance, there are two other relevant issues that I would like to begin my remarks by addressing.”
“As many of you already know, this is my first earnings call since I joined Assertio a little over two months ago, and I'm very excited to be here. Over the past couple of months, I've been asked by a variety of stakeholders why I joined Assertio.”
Assertio Holdings, Inc.
Board Member
Proxy statement
2024-01-01–present
Last confirmed April 8, 2025
2015-01-01–2021-07-19
Assertio Holdings, Inc.
CEO
Proxy statement
Start not stated–2025-04-08
Last confirmed by a filing; no departure on record
Proxy statement
Start not stated–2021-04-21
Last confirmed by a filing; no departure on record
Proxy statement
Start not stated–2022-04-29
Last confirmed by a filing; no departure on record
Assertio Holdings, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Assertio Holdings, Inc. | CEO | $721,933 | $1,884,984 |
| 2024 | Assertio Holdings, Inc. | CEO | $502,372 | $3,012,703 |
| 2021 | American Well Corp (AMWL) | Chief Commercial and Growth Officer | $181,875 | $8,889,780 |
| 2020 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, NorthAmerica Commercial | $776,923 | $4,126,283 |
| 2019 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, NorthAmerica Commercial | $676,923 | $3,462,290 |
Assertio Holdings, Inc. Q2 FY2025 Earnings Call
Assertio Holdings, Inc.
Assertio Holdings, Inc. Q1 FY2025 Earnings Call
Assertio Holdings, Inc.
Assertio Holdings, Inc. Q4 FY2024 Earnings Call
Assertio Holdings, Inc.
Assertio Holdings, Inc. Q3 FY2024 Earnings Call
Assertio Holdings, Inc.
Assertio Holdings, Inc. Q2 FY2024 Earnings Call
Assertio Holdings, Inc.
